Can you buy Anduril stock?
As of November 6, 2026, Anduril is privately held, so you can’t buy its shares through ordinary public stock-exchange trading. There is no public Anduril ticker or exchange share price. Private-market offers, where available, involve a different set of eligibility rules, ownership rights and resale restrictions.
The attraction is easy to understand. Autonomous defense technology sounds a little more exciting than another spreadsheet tab. But the interesting investment question starts after the impressive hardware: what would you actually own, at what valuation, and with what way to sell?
Those questions matter whether you’re researching Anduril itself or a public company connected to it.
What does Anduril do?
Anduril develops defense technology, including autonomous systems and its Lattice software platform. Its description of its business model emphasizes funding its own research and development and building products for military customers.
That combination makes this more than a software story. Developing systems, building manufacturing capacity and delivering working equipment all require capital. An investor would want to understand how product development turns into customer orders, completed deliveries and cash collected.
A compelling demonstration can help explain the technology. It cannot answer questions about margins, production costs or the financing needed to expand.
Who owns Anduril?
Anduril has private shareholders rather than a publicly traded parent company. In May 2026, Anduril raised additional private capital. Transaction counsel Gunderson Dettmer confirmed a $5 billion raise at a $61 billion valuation, led by Thrive Capital and Andreessen Horowitz.
Those are financing figures, not a stock quote. They do not tell an individual buyer which share class is available, what rights accompany it or whether a seller’s asking price is reasonable.
New financing can also change existing investors’ percentage ownership. Before comparing two transactions, check the dates, securities and valuation basis rather than assuming every reported number measures the same thing.
Does a public partner offer Anduril exposure?
A commercial relationship can matter to a public company’s business without giving that company an ownership stake in Anduril. For example, Anduril and Meta announced an extended-reality partnership in May 2025. Buying a partner’s shares does not automatically buy a slice of Anduril.
The useful distinction is between a shareholder, a supplier, a customer and a collaborator. These relationships create different opportunities and risks. A contract might contribute revenue to a supplier; an equity investment might change in value. Neither makes the two companies interchangeable.
The same applies to defense funds. A portfolio of publicly traded defense businesses can provide sector exposure, but its name alone does not establish that it owns Anduril. Read its actual holdings and investment structure before treating it as a substitute.
What should you check in a private-share offer?
Anduril’s own investor warning is more specific: it says the company does not currently offer retail investment opportunities or equity or debt through third-party brokers or agents. Most shareholders need Anduril’s consent to transfer shares. The company also warns that unauthorized forward contracts intended to get around its transfer restrictions may have no value. A pitch promising access is not proof that the seller can deliver it.
Start with the legal entity and the security. Are you purchasing company shares directly, or an interest in a special-purpose vehicle that owns shares? In the second arrangement, fees, voting arrangements and distribution rules may sit between you and the underlying company.
Then ask practical questions:
- Which share class is involved, and what rights does it carry?
- Does the seller have the right to transfer it?
- What are the complete transaction and ongoing fees?
- What financial information will you receive?
- How could you exit if there is no IPO?
The SEC’s private-placement guidance explains that these investments can be difficult to resell, provide limited disclosure and involve the risk of losing the entire investment. Eligibility depends on the offering; being eligible does not make an offer suitable.
What would make an Anduril IPO worth evaluating?
An IPO prospectus would provide a different research starting point from a funding headline. Important details would include revenue concentration, margins, cash use, debt, share classes and the number of shares being offered. An announced intention to list would still be different from a completed offering.
For a manufacturing-heavy expansion, cash deserves particular attention. StockHitter’s free cash flow guide explains why investment spending can change the picture presented by earnings alone. The relevant question is whether the business can finance its ambitions on acceptable terms, not simply whether demand sounds large.
Until public shares are available, keep the company and the investment vehicle separate. Anduril may be worth following without making a private offer attractive at any price. Our stock analysis hub provides a broader starting point for evaluating the businesses behind investment ideas.